General Announcement::SGX welcomes iX Biopharma Ltd to Catalist

Issuer & Securities

Issuer/ Manager
SINGAPORE EXCHANGE LIMITED
Securities
SINGAPORE EXCHANGE LIMITED - SG1J26887955 - S68
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
22-Jul-2015 09:07:21
Status
New
Announcement Sub Title
SGX welcomes iX Biopharma Ltd to Catalist
Announcement Reference
SG150722OTHRRI4C
Submitted By (Co./ Ind. Name)
Patricia Choo
Designation
Head of Media Communications
Description (Please provide a detailed description of the event in the box below)
Singapore Exchange (SGX) today welcomed iX Biopharma Ltd (iX Biopharma) to Catalist under the stock code 42C .

iX Biopharma is a Singapore incorporated pharmaceutical company focused on the development and commercialisation of products for the treatment of acute pain and erectile dysfunction. It also provides chemical analysis services for pharmaceutical products. iX Biopharma manages and undertakes its research and development in Singapore and Australia.

Professor Paul Edward Rolan, Director of Drug Development, iX Biopharma said, This listing is significant as it brings us a step closer towards our goal of commercialising our products currently under development. We are also heartened by the confidence that our shareholders have in the Company. We look forward to completing our clinical trials in a timely manner, and promise to work hard to create good value for them.

Mohamed Nasser Ismail, Head of SME Development & Listing, SGX, said, We are pleased to welcome iX Biopharma to SGX. With an increasing focus on healthcare and improved therapies in the region, iX Biopharma is well-placed to benefit from the resultant growth in its industry. We look forward to supporting the company on its growth journey.

The listing of iX Biopharma brings the total number of healthcare companies on SGX to 31 with a combined market capitalisation of over S$38 billion. Following iX Biopharma s IPO, the Catalist board will have 160 companies with a total market capitalisation of about S$10 billion.

iX Biopharma opened at $0.495 today, 8% up from the offer price.

Attachments